Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q1 2022 · 10-Q
Revenue$1.45M$1.45M−18.2% vs Q1 2021 Net Income-$18.79M-$18.79MN/M vs Q1 2021 EPS Diluted-$0.31-$0.31N/M vs Q1 2021 Operating Income-$18,907,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
Free Cash Flowderived-$21,133,000— Margins · derivedOperating margin-1301.2%+304.2 pt vs Q1 2021
Net margin-1293.1%+325.0 pt vs Q1 2021
ended Mar 31, 2022 · filed May 10, 2022 · 40 d after period end